Germany news - the latest biotech news from Labiotech.eu

Home Germany Page 20

Latest Posts

Screenshot 2016 12 19 at 4.24.40 PM e1482161199959

News and Trends 21 Dec 2016

Can partnerships between Biotechs and Academia be the Key to Success?

We had the opportunity to hear the story behind the successful Evotec by Thomas Hanke, Executive VP, who gave plenty of advice for biotech companies seeking to grow. One of the biggest biotechs in Europe, with over 1,000 employees, Evotec is now transitioning from offering services to other companies to building its own pipeline. Thomas Hanke, Executive […]

December 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 534516325

News and Trends 19 Dec 2016

Evotec closes the year partnering with Celgene to treat Alzheimer’s

Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug discovery CRO based in Germany that has managed to sign partnerships with some of the biggest names in Biotech. In addition to previous deals with Bayer, Merck, […]

December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 534311161

News and Trends 19 Dec 2016

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents one of the largest financial burdens in society. Now the sixth leading cause of death for all age groups, the neurodegenerative disease cost the US […]

December 19, 2016 - 7 minutesmins - By Evelyn Warner

Screenshot 2016 12 16 at 10.22.38 AM e1481880436689

News and Trends 16 Dec 2016

This Gene Therapy Startup is Showing Off with a Better Viral Vector

GeneQuine wants to be one of the first to use gene therapy to treat osteoarthritis! Watch Kilian Guse’s pitch at Labiotech Refresh to find out how his startup plans to do this. “Osteoarthritis is the most common joint disorder. (…) Currently, there are only symptomatic treatments but no disease-modifying treatment“. One of the major challenges is efficient drug […]

December 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 534276544

News and Trends 16 Dec 2016

Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis

Amcure and TILT Biotherapeutics announced yesterday new financing rounds supporting the development of unique strategies to cure cancer metastasis. Amcure, in Germany, is fighting highly metastatic forms of cancer by targeting angiogenesis. The company just closed a Series B round with a total of €6M from already existing investors. With the funds, Amcure plans to accelerate […]

December 16, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

8834079742 80e7d10dd6 k

News and Trends 14 Dec 2016

UPDATE: Bayer seals deal with Monsanto in Dark Side slide

Bloomberg reports that Bayer has increased its bid once more to acquire the world’s least ethical company in order to solidify its position in agrochemicals. Bayer appears hell-bent on a Faustian bargain with Monsanto: the German chemical company has just thrown more money at America’s fourth most hated company in the hope of acquiring it. Despite its […]

December 14, 2016 - 3 minutesmins - By Evelyn Warner

ADVERTISEMENT

Yuval Helfman

News and Trends 13 Dec 2016

European Pharma closes 2016 by launching new Biotech Startups

Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are launching US-based startups in oncolytic virus and stem cell therapies. Pharma is wrapping up 2016 by investing in a pair of new ventures. Bayer and Versant have invested $225M to launch BlueRock Therapeutics, which will focus on CNS and cardiovascular diseases. This comes […]

December 13, 2016 - 2 minutesmins - By Evelyn Warner

LeStudio

News and Trends 12 Dec 2016

A New Antibiotic from Your Nose! Thanks to Functional Genomics

Could your nose lead to major discoveries in antibiotic production? Genome mining of nose bacteria has revealed a new powerful antibiotic. Functional genomics offers a powerful tool for the isolation and detection of novel antibiotics, as the data obtained from it can be used to describe gene functions and interactions. The human microbiome has been largely […]

December 12, 2016 - 2 minutesmins - By Joachim Eeckhout

shutterstock 527874877

News and Trends 8 Dec 2016

The Munich Biotech Mafia expand to the US with a New TCR Startup

TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […]

December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

molecule dna alice photo lq

News and Trends 5 Dec 2016

Another Pharma sloughs off Small Molecules to focus on Biologics

BI has taken an axe to its small molecule discovery program in order to focus on immuno-oncology in the latest farewell to old-school chemical drugs. Over 90% of the drugs on the market today are small molecules, but the bell has been tolling for these therapies for some time now as biopharma is increasingly focused […]

December 5, 2016 - 2 minutesmins - By Evelyn Warner

shutterstock 524832742

News and Trends 1 Dec 2016

Evotec gets hold of CRISPR in a new Partnership with Merck

Evotec teamed up with Merck to boost its drug discovery services with CRISPR, entering the battlefield for the patent behind the discovery of the century. Apart from being a pioneer in the translation of research from academia to the clinic, Evotec is a successful CRO with top-level partners including Bayer, Roche, Sanofi, Boehringer Ingelheim and Takeda. The German company is […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 340710203

News and Trends 30 Nov 2016

FDA and EMA review the First Therapy for a Deadly Skin Cancer

Merck and Pfizer have been granted priority review by the FDA for the first treatment dealing with one of the most aggressive forms of skin cancer. The FDA has accepted Merck and Pfizer‘s market application for avelumab in metastatic Merkel cell carcinoma (MCC) with priority review. Just a month ago, the EMA also accepted their application. If […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT